Current Report Filing (8-k)
April 04 2017 - 4:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 30, 2017
Protea Biosciences Group, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
000-51474
|
20-2903252
|
(State or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
1311 Pineview Drive,
Suite 501
Morgantown, West Virginia 26505
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code:
|
(304) 292-2226
|
(Former Name of Former Address, if Changed
Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
On March 2, 2017, Protea
Biosciences Group, Inc., (the “Company”) filed with the Securities and Exchange Commission a definitive schedule 14A
consent solicitation statement (the “Consent Solicitation”) and thereafter mailed the Consent Solicitation to all Company
stockholders as of February 21, 2017 (the “Record Date”). Under the Consent Solicitation, as filed with the Securities
and Exchange Commission, the Company expressly reversed the right, as determined in its sole discretion, to extend the deadline
to receive written consents from Company shareholders, as of the Record Date.
On March 30, 2017 the
Company’s board of directors approved the Company’s decision to exercise such discretionary right by extending the
deadline to receive written consents under the Consent Solicitation from the original date of March 30, 2017 to the revised date
of April 28, 2017.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: April 4, 2017
|
PROTEA BIOSCIENCES GROUP, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Stephen Turner
|
|
|
Stephen Turner
|
|
|
Chief Executive Officer
|